HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer

BACKGROUND: Given the immunogenicity of NYESO-1 peptides in prostate cancer, a phase I clinical trial was designed to evaluate HLA class-I and class-II restricted NYESO-1 peptides in metastatic castration-resistant prostate cancer (mCRPC). METHODS: Patients with progressive mCRPC, Zubrod Performance...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sonpavde, Guru, Wang, Mingjun, Peterson, Leif E., Wang, Helen Y., Joe, Teresa, Mims, Martha P., Kadmon, Dov, Ittmann, Michael M., Wheeler, Thomas M., Gee, Adrian P., Wang, Rong-Fu, Hayes, Teresa G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4100683/
https://ncbi.nlm.nih.gov/pubmed/23609828
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-013-9960-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados